Sean Wirtjes Sells 7,480 Shares of Rapid Micro Biosystems (NASDAQ:RPID) Stock

12 Mar 2026, 20:42 by Scott Moore · The Cerbat Gem

Rapid Micro Biosystems, Inc. (NASDAQ:RPID – Get Free Report) CFO Sean Wirtjes sold 7,480 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total transaction of $32,313.60. Following the transaction, the chief financial officer directly owned 556,194 shares of the company’s stock, valued at $2,402,758.08. The trade was a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Rapid Micro Biosystems Price Performance

NASDAQ RPID traded down $0.96 on Thursday, reaching $3.42. The company’s stock had a trading volume of 514,590 shares, compared to its average volume of 133,521. Rapid Micro Biosystems, Inc. has a 52 week low of $1.86 and a 52 week high of $4.94. The company has a current ratio of 4.23, a quick ratio of 2.95 and a debt-to-equity ratio of 0.42. The firm has a market cap of $151.58 million, a PE ratio of -3.39 and a beta of 1.38. The business has a 50-day moving average price of $3.97 and a 200 day moving average price of $3.54.

Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). The business had revenue of $11.28 million for the quarter, compared to the consensus estimate of $10.93 million. Rapid Micro Biosystems had a negative return on equity of 73.90% and a negative net margin of 145.11%. Sell-side analysts expect that Rapid Micro Biosystems, Inc. will post -1.1 EPS for the current year.

Wall Street Analysts Forecast Growth

RPID has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $8.00.

View Our Latest Research Report on Rapid Micro Biosystems

Rapid Micro Biosystems News Summary

Here are the key news stories impacting Rapid Micro Biosystems this week:

Positive Sentiment: New multi-system order from Samsung Biologics reinforces commercial traction for the Growth Direct automation platform and expands deployment across a large CDMO customer network — a clear revenue-growth catalyst. Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics
Positive Sentiment: Company reported record Q4 and full‑year 2025 revenue (Q4 revenue $11.3M, FY2025 $33.6M), and Q4 revenue beat the Street — evidence demand and placements are growing. Rapid Micro Biosystems Reports Record Fourth Quarter and Full-Year 2025 Financial Results
Neutral Sentiment: Earnings call transcript and summaries provide color on growth initiatives and customer pipeline but did not materially change the near‑term outlook; read for management commentary on placements, margin drivers and execution risks. Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript
Negative Sentiment: EPS missed expectations (reported ($0.28) vs. consensus ($0.23)), and profitability remains weak (large negative net margin and negative ROE) — these metrics keep the stock in a riskier profile and may slow multiple expansion. RPID Earnings / Conference Call
Negative Sentiment: The company issued FY2026 revenue guidance of $37.0M–$41.0M (management expects ~30–38 system placements) — the midpoint is slightly below consensus (~$39.7M), which, combined with high operating losses, likely weighed on sentiment. 2026 Guidance in Press Release
Negative Sentiment: Recent insider selling by CEO, CFO and COO (multiple Form 4 filings show sales in March) can amplify downward pressure on the stock even if sales are for diversification or liquidity. SEC Form 4 — Spignesi sale

Hedge Funds Weigh In On Rapid Micro Biosystems

Institutional investors have recently modified their holdings of the stock. Hudson Bay Capital Management LP acquired a new position in shares of Rapid Micro Biosystems during the third quarter worth approximately $38,000. Fifth Lane Capital LP acquired a new stake in shares of Rapid Micro Biosystems in the fourth quarter valued at approximately $51,000. American Century Companies Inc. raised its position in Rapid Micro Biosystems by 46.1% in the 2nd quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after purchasing an additional 5,341 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new position in Rapid Micro Biosystems in the 4th quarter worth approximately $71,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Rapid Micro Biosystems during the 4th quarter worth $72,000. 52.60% of the stock is owned by institutional investors.

Rapid Micro Biosystems Company Profile

(Get Free Report)

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.